Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

159 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Autologous stem-cell transplantation as consolidation of first-line chemotherapy in patients with peripheral T-cell lymphoma: a multicenter GELTAMO/FIL study.
García-Sancho AM, Bellei M, López-Parra M, Gritti G, Cortés M, Novelli S, Panizo C, Petrucci L, Gutiérrez A, Dlouhy I, Bastos-Oreiro M, Sancho JM, Ramírez MJ, Moraleda JM, Carrillo E, Jiménez-Ubieto AI, Jarque I, Orsucci L, García-Torres E, Montalbán C, Dodero A, Arranz R, De Las Heras N, Pascual MJ, López-Jiménez J, Spina M, Re A, De Villambrosia SG, Bobillo S, Federico M, Caballero D. García-Sancho AM, et al. Among authors: montalban c. Haematologica. 2022 Nov 1;107(11):2675-2684. doi: 10.3324/haematol.2021.279426. Haematologica. 2022. PMID: 35320921 Free PMC article.
First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial.
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver FJ, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C; Grupo Español de Linfomas/Trasplante de Médula Ósea (GELTAMO). Salar A, et al. Among authors: montalban c. Lancet Haematol. 2014 Dec;1(3):e104-11. doi: 10.1016/S2352-3026(14)00021-0. Epub 2014 Nov 19. Lancet Haematol. 2014. PMID: 27029228
Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of β2 -microglobulin yields a more accurate GELTAMO-IPI.
Montalbán C, Díaz-López A, Dlouhy I, Rovira J, Lopez-Guillermo A, Alonso S, Martín A, Sancho JM, García O, Sánchez JM, Rodríguez M, Novelli S, Salar A, Gutiérrez A, Rodríguez-Salazar MJ, Bastos M, Domínguez JF, Fernández R, Gonzalez de Villambrosia S, Queizan JA, Córdoba R, de Oña R, López-Hernandez A, Freue JM, Garrote H, López L, Martin-Moreno AM, Rodriguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators. Montalbán C, et al. Br J Haematol. 2017 Mar;176(6):918-928. doi: 10.1111/bjh.14489. Epub 2017 Jan 20. Br J Haematol. 2017. PMID: 28106247 Free article.
Long-term results of a phase 2 study of rituximab and bendamustine for mucosa-associated lymphoid tissue lymphoma.
Salar A, Domingo-Domenech E, Panizo C, Nicolás C, Bargay J, Muntañola A, Canales M, Bello JL, Sancho JM, Tomás JF, Rodríguez MJ, Peñalver J, Grande C, Sánchez-Blanco JJ, Palomera L, Arranz R, Conde E, García M, García JF, Caballero D, Montalbán C. Salar A, et al. Among authors: montalban c. Blood. 2017 Oct 12;130(15):1772-1774. doi: 10.1182/blood-2017-07-795302. Epub 2017 Aug 11. Blood. 2017. PMID: 28801448 Free article. Clinical Trial. No abstract available.
Differential prognostic impact of GELTAMO-IPI in cell of origin subtypes of Diffuse Large B Cell Lymphoma as defined by the Hans algorithm.
Montalbán C, Díaz-López A, Martín A, Baile M, Sanchez JM, Sancho JM, García O, Novelli S, Monter-Rovira A, Salar A, Bastos M, Gutiérrez A, Bento L, Córdoba R, Arquero T, González de Villambrosia S, Barranco G, De Oña R, López Guillermo A, Rodriguez Salazar MJ, Domínguez JF, Fernández R, Queizan JA, Rodríguez J, Abraira V, García JF; GELTAMO-IPI Project Investigators. Montalbán C, et al. Br J Haematol. 2018 Aug;182(4):534-541. doi: 10.1111/bjh.15446. Epub 2018 Jul 5. Br J Haematol. 2018. PMID: 29978453 Free article.
Spanish Lymphoma Group (GELTAMO) guidelines for the diagnosis, staging, treatment, and follow-up of diffuse large B-cell lymphoma.
González-Barca E, Coronado M, Martín A, Montalbán C, Montes-Moreno S, Panizo C, Rodríguez G, Sancho JM, López-Hernández A; Spanish Lymphoma Group (GELTAMO). González-Barca E, et al. Among authors: montalban c. Oncotarget. 2018 Aug 17;9(64):32383-32399. doi: 10.18632/oncotarget.25892. eCollection 2018 Aug 17. Oncotarget. 2018. PMID: 30190794 Free PMC article. Review.
Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Peñalver FJ, Márquez JA, Durán S, Giraldo P, Martín A, Montalbán C, Sancho JM, Ramírez MJ, Terol MJ, Capote FJ, Gutiérrez A, Sánchez B, López A, Salar A, Rodríguez-Caravaca G, Canales M, Caballero MD; GELTAMO (The Spanish Lymphoma Cooperative Group). Peñalver FJ, et al. Among authors: montalban c. Cancer Med. 2019 Nov;8(16):6955-6966. doi: 10.1002/cam4.2555. Epub 2019 Oct 1. Cancer Med. 2019. PMID: 31573746 Free PMC article. Clinical Trial.
Evaluation of the MD Anderson tumor score for diffuse large B-cell lymphoma in the rituximab era.
Gutierrez A, Bento L, Diaz-Lopez A, Barranco G, Garcia-Recio M, Lopez-Guillermo A, Dlouhy I, Rovira J, Rodriguez M, Sanchez Pina JM, Baile M, Martín A, Novelli S, Sancho JM, García O, Salar A, Bastos-Oreiro M, Rodriguez-Salazar MJ, Fernandez R, de la Cruz F, Queizan JA, González de Villambrosia S, Cordoba R, López A, Luzardo H, García D, Sastre-Serra J, Garcia JF, Montalban C, Cabanillas F, Rodríguez J. Gutierrez A, et al. Among authors: montalban c. Eur J Haematol. 2020 May;104(5):400-408. doi: 10.1111/ejh.13364. Epub 2020 Feb 18. Eur J Haematol. 2020. PMID: 31804029 Free PMC article.
A randomized phase II study comparing consolidation with a single dose of 90Y ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results.
López-Guillermo A, Canales MÁ, Dlouhy I, Mercadal S, Briones J, Martín García-Sancho A, Sancho JM, Moraleda JM, Terol MJ, Salar A, Palomera L, Gardella S, Jarque I, Ferrer S, Bargay J, López A, Panizo C, Muntañola A, Montalbán C, Conde E, Hernández MT, Soler A, García Marco JA, Deben G, Marín J, Tomás JF; PETHEMA/GELTAMO/GELCAB Spanish Intergroup. López-Guillermo A, et al. Among authors: montalban c. Leuk Lymphoma. 2022 Jan;63(1):93-100. doi: 10.1080/10428194.2021.1971216. Epub 2021 Aug 30. Leuk Lymphoma. 2022. PMID: 34459702 Clinical Trial.
Low-risk HPLLs/ABC score patients with splenic marginal zone lymphoma can be safely managed without treatment: Results from a prospective Spanish study.
Muntañola A, Villalobos MT, González-Villambrosia S, Rodríguez-Salazar MJ, Jiménez-Ubieto A, Bastidas-Mora G, Córdoba R, Infante M, Vidal MJ, Díaz FJ, Baile M, Bastos-Oreiro M, Panizo C, Sancho JM, Navarro B, García T, Escoda L, Abrisqueta P, Terol MJ, de Campo R, Mozas P, López-Guillermo A, Salar A, Montalbán C; GELTAMO group (Grupo Español de Linfomas y Trasplante de Médula Ósea). Muntañola A, et al. Among authors: montalban c. Br J Haematol. 2023 Aug;202(4):776-784. doi: 10.1111/bjh.18912. Epub 2023 Jun 30. Br J Haematol. 2023. PMID: 37386877
159 results